All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 3rd NCRI AML Academy, the AML Hub was pleased to speak with David Taussig, The Royal Marsden Hospital, London, UK. We asked, Should Venetoclax based induction regimens be considered standard of care for 60+ adults?
Should Venetoclax based induction regimens be considered SOC for 60+ adults?
Taussig begins by highlighting that for adults not fit for intensive chemotherapy, evidence favors the use of venetoclax + azatadine. He goes on to outline AML subtypes that can benefit from venetoclax regimens in fit patients, discussing FLT-3 mutations and the BELLINI trial.
The impact of targeted treatment and immunotherapies on the role of hematopoietic stem cell transplantation in the treatment of blood cancers
Steven M. Bair and colleagues recently published a review in Cancer on the current role of HSCT in the...
ASH 2018 | Venetoclax-based therapies for patients with acute myeloid leukemia who are ineligible for intensive chemotherapy
At the 60th ASH Annual Meeting & Exposition, there were several talks focused on the use of venetoclax in combination with...
Subscribe to get the best content related to AML delivered to your inbox